Literature DB >> 11817709

Direct measurement of IGF-I and IGFBP-3 in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis.

L Pala1, S Giannini, E Rosi, B Cresci, G Scano, S Mohan, R Duranti, C M Rotella.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by the rearrangement of extracellular matrix and progressive increase in the amount of fibrotic tissue in the lung. IGF-I is a potent profibrogenic molecule and its bioavailability is dependent on at least 6 binding proteins called IGFBPs. Among these, IGFBP-3 is the most represented in serum and in different connective tissues. The purpose of this study was to identify and characterize IGFBP-3 in bronchoalveolar lavage (BAL) fluids. We studied 11 patients with IPF and 6 normal subjects by performing baseline pulmonary function test and BAL. IGF-I and IGFBP-3 were measured by RIA in BAL and serum. No significant differences were observed between serum IGF-I and IGFBP-3 from IPF patients and normal subjects. Instead, the direct measurement in BAL revealed a significant increase of IGF-I and IGFBP-3 in IPF patients compared to normal subjects. BAL IGF-I and IGFBP-3 concentrations were significantly related to inspiratory vital capacity (IVC) and carbon dioxide partial pressure (PaCO2): the higher the value of IVC and the lower the value of PaCO2, the higher the level of IGF-I and IGFBP-3. In conclusion, IGFBP3 and IGF-I could be important local mediators of IPF. Their direct measurement in BAL in IPF patients could be used as a clinical marker of the disease, since high levels of IGFBP-3 and IGF-I in BAL are associated to the initial phase of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817709     DOI: 10.1007/BF03343942

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity.

Authors:  L C Giudice; E M Farrell; H Pham; G Lamson; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

Review 2.  Insulin-like growth factor binding protein control secretion and mechanisms of action.

Authors:  D R Clemmons
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

Review 3.  Insulin-like growth factor binding proteins.

Authors:  M M Rechler
Journal:  Vitam Horm       Date:  1993       Impact factor: 3.421

Review 4.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.

Authors:  S Rajaram; D J Baylink; S Mohan
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

Review 5.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.

Authors:  A L Katzenstein; J L Myers
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

6.  Clinical significance of pulmonary function tests. Pulmonary function testing in interstitial pulmonary disease. What does it tell us?

Authors:  B A Keogh; R G Crystal
Journal:  Chest       Date:  1980-12       Impact factor: 9.410

7.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency.

Authors:  W F Blum; M B Ranke; K Kietzmann; E Gauggel; H J Zeisel; J R Bierich
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

8.  Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung.

Authors:  S Homma; I Nagaoka; H Abe; K Takahashi; K Seyama; T Nukiwa; S Kira
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

9.  Patterns of pulmonary structural remodeling after experimental paraquat toxicity. The morphogenesis of intraalveolar fibrosis.

Authors:  Y Fukuda; V J Ferrans; C I Schoenberger; S I Rennard; R G Crystal
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

10.  Studies on the regulation of insulin-like growth factor binding protein 3 secretion in human osteosarcoma cells in vitro.

Authors:  Y Nakao; S Hilliker; D J Baylink; S Mohan
Journal:  J Bone Miner Res       Date:  1994-06       Impact factor: 6.741

View more
  9 in total

1.  IGF1 and IGFBP3 in acute respiratory distress syndrome.

Authors:  Amy M Ahasic; Rihong Zhai; Li Su; Yang Zhao; Konstantinos N Aronis; B Taylor Thompson; Christos S Mantzoros; David C Christiani
Journal:  Eur J Endocrinol       Date:  2011-10-17       Impact factor: 6.664

2.  Altered expression of type I insulin-like growth factor receptor in Crohn's disease.

Authors:  F El Yafi; R Winkler; P Delvenne; N Boussif; J Belaiche; E Louis
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

3.  Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury.

Authors:  Lynn M Schnapp; Samuel Donohoe; Jinzhi Chen; Donald A Sunde; Patricia M Kelly; John Ruzinski; Thomas Martin; David R Goodlett
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

4.  Radiation induced pulmonary fibrosis as a model of progressive fibrosis: Contributions of DNA damage, inflammatory response and cellular senescence genes.

Authors:  Tyler A Beach; Carl J Johnston; Angela M Groves; Jacqueline P Williams; Jacob N Finkelstein
Journal:  Exp Lung Res       Date:  2017-05-23       Impact factor: 2.459

5.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

6.  Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1.

Authors:  Huijuan Xiao; Xiaoxi Huang; Shiyao Wang; Zheng Liu; Run Dong; Dingyun Song; Huaping Dai
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

7.  Upregulation of activin-B and follistatin in pulmonary fibrosis - a translational study using human biopsies and a specific inhibitor in mouse fibrosis models.

Authors:  Marjukka Myllärniemi; Jussi Tikkanen; Juha J Hulmi; Arja Pasternack; Eva Sutinen; Mikko Rönty; Outi Leppäranta; Hongqiang Ma; Olli Ritvos; Katri Koli
Journal:  BMC Pulm Med       Date:  2014-11-01       Impact factor: 3.317

8.  IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model.

Authors:  Sergio Piñeiro-Hermida; Icíar P López; Elvira Alfaro-Arnedo; Raquel Torrens; María Iñiguez; Lydia Alvarez-Erviti; Carlos Ruíz-Martínez; José G Pichel
Journal:  Sci Rep       Date:  2017-06-27       Impact factor: 4.379

9.  Elevated Serum IGFBP-2 and CTGF Levels Are Associated with Disease Activity in Patients with Dermatomyositis.

Authors:  Min Yang; Yuehong Chen; Geng Yin; Sang Lin; Huan Liu; Yupeng Huang; Yunru Tian; Yueyuan Zhou; Fengming Luo; Qibing Xie
Journal:  Dis Markers       Date:  2022-03-20       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.